Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Sore throat (acute pharyngitis) is among the most common complaints among adults and is a reason for seeking healthcare globally. Antibiotics are widely used among patients with infectious sore throat. Previous research has indicated that corticosteroids could offer an alternative symptomatic treatment for sore throats. To estimate the corticosteroid efficacy as an additional therapy for sore throat adult patients, the literature search included PubMed, Medline, OVID, Cochrane CENTRAL, and Scopus for articles published until July 1st, 2024. The outcomes included the onset of pain relief (average time), complete resolution of pain (average time), absolute reduction of pain at 24 and 48 hours, requirement of antibiotics, and adverse effects related to treatment. Standardized mean difference (SMD) and risk difference were used to report numerical and dichotomous results. Five studies were included. Among the five included studies, corticosteroids showed significant effectiveness in resolving pain at 24 hours (average risk difference: 0.2200, 95% CI: 0.0500 to 0.3899, p = 0.0112) but with notable heterogeneity (I² = 82.4255%). At 48 hours, the benefit was not statistically significant (average risk difference: 0.4063, 95% CI: -0.1857 to 0.9984, p = 0.1786, I² = 98.9219%). Corticosteroids also decreased the average time to onset of pain relief (average SMD: -0.6590, 95% CI: -1.2857 to -0.0323, p = 0.0393, I² = 89.7914%), although with high heterogeneity. Other findings indicated a possible reduction in antibiotic use and fewer days missed from work. Adverse effects were minimal and occurred at similar rates in both corticosteroid and placebo arms. Corticosteroids can decrease pain intensity and duration in adults with acute sore throats. However, significant heterogeneity among studies and methodological limitations render the overall evidence inconclusive. While some studies noted reduced antibiotic use and lower symptom recurrence, high-quality RCTs are needed to address these limitations and provide more definitive guidelines for corticosteroid use in treating acute pharyngitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421831PMC
http://dx.doi.org/10.7759/cureus.67740DOI Listing

Publication Analysis

Top Keywords

sore throat
16
average time
12
risk difference
12
acute pharyngitis
8
onset pain
8
pain relief
8
relief average
8
pain hours
8
adverse effects
8
average risk
8

Similar Publications

Oropouche virus (OROV) is emerging as a growing public health concern, with increasing numbers of case, an expanding global spread and the potential for severe clinical outcomes. However, despite the increasing incidence, the clinical features of OROV infections have not yet been thoroughly examined. The present systematic review and meta-analysis aimed to investigate the prevalence of clinical manifestations in OROV infections.

View Article and Find Full Text PDF

Objectives In Japan, clinical diagnosis based solely on symptoms, without the use of test kits, has been adopted to enable the rapid identification of individuals infected with coronavirus disease 2019 (COVID-19). A history of close contact with COVID-19 patients is a prerequisite for such symptom-based diagnosis. However, the current diagnostic criteria lack objectivity.

View Article and Find Full Text PDF

Objective: To increase the percentage of first-line antibiotics prescribed for acute otitis media (AOM) and pharyngitis, the percentage of treated pharyngitis with a positive group A streptococcus (GAS) test, and the percentage of nonsevere AOM patients prescribed delayed antibiotics in pediatric urgent care clinics (UCCs).

Methods: The American Academy of Pediatrics Section on Urgent Care Medicine and Pediatric Acute and Critical Care Quality Network developed a multicenter quality improvement collaborative. We used national guidelines to determine criteria for nonsevere AOM and first-line antibiotics for AOM and pharyngitis.

View Article and Find Full Text PDF

Background: Between November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km).

Methods: We analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms.

View Article and Find Full Text PDF

Acute Generalized Exanthematous Pustulosis: A Case Report.

Cureus

August 2025

Internal Medicine, Centro Médico Nacional Siglo XXI, Mexico City, MEX.

Acute generalized exanthematous pustulosis (AGEP) is a rare, potentially severe cutaneous adverse reaction characterized by the rapid onset of numerous small, sterile pustules on edematous erythema, commonly accompanied by systemic symptoms such as high-grade fever and neutrophilic leukocytosis. AGEP is most frequently triggered by medications, especially antibiotics, though infections and other exposures can also be causative. We report the case of a previously healthy 27-year-old male patient who developed a febrile pustular eruption with systemic involvement.

View Article and Find Full Text PDF